Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The venue will be the Fairmont Copley Plaza in Boston.

Please contact Julie Powers Julie@worldhealthcommunications.com with your interest in attending this exciting program as space is limited.

iwMyeloma 2016

22–24 April 2016 | Fairmont Copley Plaza, Boston

iwMyeloma 2016

22–24 April 2016 | Fairmont Copley Plaza, Boston

The venue will be the Fairmont Copley Plaza in Boston.

Please contact Julie Powers Julie@worldhealthcommunications.com with your interest in attending this exciting program as space is limited.

Myeloma 2016: Panel discussion on the new treatment paradigm 11:57
Myeloma 2016: Panel discussion on the new treatment paradigm
Gareth Morgan et al. • 5 May 2016
Myeloma 2016: Panel discussion on novel treatments 13:09
Myeloma 2016: Panel discussion on novel treatments
Keith Stewart et al. • 22 Apr 2016
Mechanism of action of daratumumab 2:03
Mechanism of action of daratumumab
Niels van de Donk • 22 Apr 2016
LCL161 – a new approach to treating multiple myeloma 4:42
LCL161 – a new approach to treating multiple myeloma
Marta Chesi • 22 Apr 2016
Update on trametinib for multiple myeloma 2:14
Update on trametinib for multiple myeloma
Faith Davies • 22 Apr 2016
Perspectives on future paths to cure multiple myeloma 1:36
Perspectives on future paths to cure multiple myeloma
Antonio Palumbo • 22 Apr 2016
The importance of the microenvironment in multiple myeloma 1:08
The importance of the microenvironment in multiple myeloma
Faith Davies • 22 Apr 2016
Clinical management of venetoclax in multiple myeloma 1:28
Clinical management of venetoclax in multiple myeloma
Lawrence Boise • 22 Apr 2016
The biology of the plasma cell and drug targets in multiple myeloma 1:07
The biology of the plasma cell and drug targets in multiple myeloma
Lawrence Boise • 22 Apr 2016
Tolerability of monoclonal antibodies in multiple myeloma 1:13
Tolerability of monoclonal antibodies in multiple myeloma
Thomas Martin • 22 Apr 2016
Isatuximab for multiple myeloma – promising results and next steps 2:20
Isatuximab for multiple myeloma – promising results and next steps
Thomas Martin • 22 Apr 2016
MMRF presents highlights for patients at Myeloma 2016 5:17
MMRF presents highlights for patients at Myeloma 2016
Daniel Auclair et al. • 22 Apr 2016
PET-CT vs MRI in multiple myeloma 1:59
PET-CT vs MRI in multiple myeloma
Philippe Moreau • 22 Apr 2016
How immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma 3:06
How immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma
Jesús San Miguel • 22 Apr 2016
Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma 3:49
Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma
Jesús San Miguel • 22 Apr 2016
Venetoclax for multiple myeloma – mechanism of action and next steps 1:58
Venetoclax for multiple myeloma – mechanism of action and next steps
Lawrence Boise • 22 Apr 2016

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals